Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$2.05
+0.5%
$1.96
$1.41
$2.79
$92.72M1.4667,158 shs44,516 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$10.18
+2.2%
$10.62
$4.11
$28.68
$65.57M2.97174,543 shs26,851 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.96
+51.9%
$1.17
$7.80
$12.38
$33.81MN/A41,322 shs7.83 million shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.91
-2.6%
$1.18
$0.97
$5.07
$134.01M-0.1511,697 shs3.70 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
0.00%+11.17%-0.78%+13.97%+7.94%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+2.89%-13.01%-19.55%+35.69%+42,831.03%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00%-3.70%+8.33%+5.69%-62.86%
Zura Bio Limited stock logo
ZURA
Zura Bio
+51.94%+41.01%+71.93%+59.35%-44.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2.9448 of 5 stars
3.55.00.00.03.30.80.0
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.3927 of 5 stars
3.55.00.00.02.91.70.6
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
3.0461 of 5 stars
3.63.00.00.02.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
3.00
Buy$10.00387.80% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00499.21% Upside
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
3.13
Buy$14.33650.44% Upside

Current Analyst Ratings Breakdown

Latest JATT, FBRX, ZURA, and ENTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/9/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$180K517.63N/AN/A$0.23 per share8.91
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.07 per share27.08($0.53) per shareN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$2.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$9.54M-$0.260.00N/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.290.00N/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Zura Bio Limited stock logo
ZURA
Zura Bio
-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)

Latest JATT, FBRX, ZURA, and ENTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.21N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.19N/AN/AN/AN/AN/A
8/8/2025Q2 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.11N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/9/2025Q1 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.07-$0.06+$0.01-$0.06N/A$0.04 million
5/8/2025Q1 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.19-$0.02-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
13.07
13.07
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
8.14
8.14

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.38%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Zura Bio Limited stock logo
ZURA
Zura Bio
14.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2045.45 million40.73 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
368.38 million58.65 millionOptionable

Recent News About These Companies

3 Penny Stocks With Market Caps Over $70M Worth Watching
Zura Bio (NASDAQ:ZURA) Stock Price Up 12.5% - Should You Buy?
Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$2.05 +0.01 (+0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$2.09 +0.04 (+2.15%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$10.18 +0.22 (+2.21%)
Closing price 04:00 PM Eastern
Extended Trading
$10.25 +0.07 (+0.70%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.96 +0.67 (+51.94%)
As of 07/17/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.91 -0.05 (-2.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.94 +0.03 (+1.57%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.